Biotech Values

[DewDiligence]

The Squalamine IND in AMD has already been filed:

From page 4 of GENR’s just-filed 10K report:

http://www.sec.gov/Archives/edgar/data/880431/000119312504049198/d10k.htm

>>
In March 2004, we submitted an Investigational New Drug Application (IND) to the Food and Drug Administration of the United States (FDA) to conduct clinical trials of squalamine in ophthalmic indications including the treatment of wet AMD.
<<

Note the use of the word trials (plural)!